Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

12.2K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
12.2K
Compartment Models: Two-Compartment Model01:20

Compartment Models: Two-Compartment Model

7.7K
The two-compartment model divides the body into central and peripheral compartments to account for varying blood perfusion rates among organs and tissues, affecting drug distribution. The central compartment includes blood and highly perfused tissues with rapid drug distribution, while the peripheral compartment contains tissues with slower drug distribution. After a single IV bolus dose, the drug concentration is high in plasma and low in tissues. The drug distribution between compartments...
7.7K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

1.4K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.4K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

258
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
258
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

482
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

337
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR.

Oral oncology·2025
Same author

Anterior cruciate ligament tear patterns in young patients: An arthroscopic multicenter study.

Journal of clinical orthopaedics and trauma·2021
Same author

Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

European journal of clinical pharmacology·2012
Same author

Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.

Acta neurologica Scandinavica·2012
Same author

Immunohistochemistry and serum values of S-100B, glial fibrillary acidic protein, and hyperphosphorylated neurofilaments in brain injuries.

Soudni lekarstvi·2012
Same author

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Leukemia·2011

Related Experiment Video

Updated: Apr 4, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K

Busulfan kinetics.

H Ehrsson, M Hassan, M Ehrnebo

    Clinical Pharmacology and Therapeutics
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    This study investigated busulfan pharmacokinetics in chronic myelocytic leukemia patients. Busulfan absorption and elimination were dose-dependent, with minimal unchanged drug excreted in urine.

    More Related Videos

    Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
    09:58

    Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

    Published on: April 18, 2018

    9.7K
    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
    02:46

    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

    Published on: January 20, 2023

    5.1K

    Related Experiment Videos

    Last Updated: Apr 4, 2026

    Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
    11:25

    Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

    Published on: April 1, 2015

    14.2K
    Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
    09:58

    Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

    Published on: April 18, 2018

    9.7K
    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
    02:46

    A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

    Published on: January 20, 2023

    5.1K

    Area of Science:

    • Pharmacology
    • Oncology
    • Pharmacokinetics

    Background:

    • Chronic myelocytic leukemia (CML) treatment often involves chemotherapy.
    • Understanding the pharmacokinetic profile of drugs like busulfan is crucial for optimizing CML therapy.

    Purpose of the Study:

    • To characterize the oral pharmacokinetics of busulfan in patients with chronic myelocytic leukemia.
    • To determine the relationship between busulfan dosage and plasma concentration over time.

    Main Methods:

    • Oral administration of busulfan at doses of 2, 4, and 6 mg to CML patients.
    • Analysis of plasma concentration-time data using a one-compartment open model with zero-order absorption.
    • Calculation of pharmacokinetic parameters including elimination rate constant and area under the curve (AUC).

    Main Results:

    • Busulfan plasma concentration-time data fit a zero-order absorption, one-compartment open model.
    • The elimination rate constant averaged 0.27 +/- 0.05 hr-1.
    • Plasma AUC showed a linear relationship with the administered dose.
    • Interindividual variability was observed in absorption parameters (lag time, absorption end time, absorption rate constant).
    • Approximately 1% of the busulfan dose was excreted unchanged in urine within 24 hours.

    Conclusions:

    • Busulfan exhibits dose-proportional pharmacokinetics in CML patients following oral administration.
    • The drug is primarily eliminated via non-renal pathways, as indicated by low urinary excretion of unchanged busulfan.
    • Observed interindividual variability in absorption warrants consideration for personalized dosing strategies.